Peter Michalak, MD
Family Medicine · Tucson, AZNPI 1104321777
Payments from drug & device makers
Across 118 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$618
- Amgen$317
- AbbVie$165
- GSK$137
- Pfizer$130
- Novo Nordisk$98
- plus $734 from 18 others
What the payments were for
- Food & beverage$2,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $618 |
| Amgen | 29 | $317 |
| AbbVie | 9 | $165 |
| GSK | 7 | $137 |
| Pfizer | 8 | $130 |
| Novo Nordisk | 6 | $98 |
| Lilly USA, LLC | 5 | $96 |
| Bayer | 4 | $70 |
| Merck | 4 | $65 |
| Nevro Corp. | 3 | $61 |
| Sanofi Pasteur Inc. | 3 | $59 |
| Exact Sciences | 3 | $58 |
| Eisai Inc. | 2 | $49 |
| Johnson & Johnson | 2 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Boston Scientific | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Novartis | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,201 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 37 | $54,823 |
| JardianceEmpagliflozin | 45 | $49,023 |
| OzempicSemaglutide | 35 | $39,538 |
| EliquisApixaban | 31 | $39,224 |
| XareltoRivaroxaban | 13 | $19,212 |
| FarxigaDapagliflozin Propanediol | 15 | $14,508 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,728 |
| MyrbetriqMirabegron | 11 | $12,668 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,018 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $3,608 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $3,552 |
| NovologInsulin Aspart | 16 | $3,485 |
| SynthroidLevothyroxine Sodium | 43 | $2,769 |
| Atorvastatin Calcium | 349 | $2,483 |
| Esomeprazole Magnesium | 13 | $2,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $96 | $54,82337 claims |
| Boehringer IngelheimJardiance | $13 | $49,02345 claims |
| Novo NordiskOzempic, Novolog | $98 | $43,02351 claims |
| PfizerEliquis | $130 | $39,22431 claims |
| Johnson & JohnsonXarelto | $37 | $19,21213 claims |
| AstraZenecaFarxiga, Symbicort | $618 | $18,52628 claims |
| GSKTrelegy Ellipta | $137 | $12,72819 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $12,66811 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $3,55213 claims |
| AbbVieSynthroid | $165 | $2,76943 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $34 | $2,034251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.